## **Supplementary Material**

1. Supplementary Figures and Tables

## 1.1. Supplementary Figures

A high-quality copy of all supplementary figures are available as separate files.



Supplementary Figure 1: Flowchart of key methods during sequencing libraries preparation.



**Supplementary Figure 2: Read lengths for each 16S rRNA amplicon-specific dataset.** Histograms with distribution of read lengths in bp. Read lengths for sequences not associated with any of the amplicons of interest (unknown) are also shown. R1, forward reads; R2, reverse reads.



**Supplementary Figure 3: Amplicon sequence variants (ASVs) rarefaction curves for each 16S rRNA amplicon-specific dataset.** Each curve depicts a library. Reads were selected by random subsampling without replacement at incremental steps of 50 reads. Plots were truncated at sequencing depth equals 100,000 reads.



**Supplementary Figure 4: Taxonomic resolution for each 16S rRNA amplicon-specific dataset.** (A) Percentage of sequences with assigned taxonomy (per taxonomic level) for each amplicon-specific dataset when using Greengenes as reference database. (B) Percentage of sequences with assigned taxonomy (per taxonomic level) for each amplicon-specific dataset when using NCBI 16S RefSeq as reference database.



**Supplementary Figure 5: Amplicon sequence variant (ASV) lengths for each 16S rRNA amplicon-specific dataset.** Histograms with distribution of ASV lengths in bp. The median ASV size per amplicon-specific dataset is indicated by a red dotted line.



Supplementary Figure 6: Phyla and genera detected in each 16S rRNA amplicon-specific dataset. (A) Heatmap depicting the phyla detected in each amplicon-specific dataset. (B) Heatmap depicting the genera detected in each amplicon-specific dataset. Taxa are sorted based on the number of amplicon-specific datasets in which they were detected.



cteria

Burk

1.00

5.18

12.60

23.30

37.30

54.50

75.00

observed genera



Nodes

1.00

2.47

6.89 6.89 0 14.20 0

24.60

37.80

54.00

1.00

75.00

**Supplementary Figure 7: Taxonomic tree of each 16S rRNA amplicon-specific dataset.** Taxa detected in each amplicon-specific dataset are shown up to genus level (tree leaves). Node sizes and color scheme represent the number of leaves (number of genera) present in the subtree of the nodes. The Reingold-Tilford layout was used.



Supplementary Figure 8: Taxa (phylum to species level) relative abundances for each library as profiled by different 16S rRNA amplicons. Only the 32 most abundant taxa are shown (based on minimum relative abundance in at least one sample).



**Supplementary Figure 9: Richness and taxonomic composition of Sidle-reconstructed datasets.** (A) Fold-increase in taxonomic richness of combinations of two (averaged over all pairs) or six amplicons (as built with Sidle) in comparison with the average taxonomic richness found across amplicon-specific datasets. (B) Percentage of sequences with assigned taxonomy (per taxonomic level) for each amplicon-specific or Sidle-reconstructed dataset. (C) Average species relative abundance per amplicon-specific or Sidle-reconstructed dataset. Only the 32 most abundant species are shown (based on minimum relative abundance in at least one sample, which is adjusted for each plot).



Supplementary Figure 10: Taxa (phylum to species level) relative abundances for each library as profiled by different 16S rRNA amplicons and Sidle-reconstructed combinations. Only the 32 most abundant taxa are shown (based on minimum relative abundance in at least one sample).

## **1.2.** Supplementary Tables

Patient	Condition	Samples			
#1	BPH	#1			
#2	BPH	#2			
#3	BPH	#3			
#4	BPH	#4			
#5	BPH	#5			
#6	BPH	#6			
#7	NMIBC	#7.1, #7.2, #7.3			
#8	NMIBC	#8.1, #8.2			
#9	NMIBC	#9.1, #9.2			
#10	NMIBC	#10.1, #10.2			
#11	NMIBC	#11.1*, #11.2*			
#12	NMIBC	#12.1*, #12.2*			
#13	NMIBC	#13.1, #13.2			
#14	BPH	#14			
SC	-	#15			
NC	-	#16			

**Supplementary Table 1: Patients and samples included in the study.** Samples not sequenced due to low target sequence concentration are indicated with an asterisk. NMIBC patients had two or three samples collected longitudinally during the treatment course. BPH, benign prostatic hyperplasia; NMIBC, non-muscle invasive bladder cancer; SC, Smart Control; NC, DNA extraction negative control.

	Amplicon	Primers F	'rimers F Primers R Length (I		%GC (F/R)	DI (F/R)	Names (F/R)	Amplicon length
	ITS	CTTGGTCATTTAGAGGAAGTAA	GCTGCGTTCTTCATCGATGC	22/20	36/55	0/0	ITS1F/ITS2	230
	V1V2	AGRGTTTGATYMTGGCTC	CTGCTGCCTYCCGTA	18/15	39-56/60-67	3/1	27F/357R	330
	V2V3	GGCGNACGGGTGAGTAA	WTTACCGCGGCTGCTGG	17/17	59-65/65	3/1	104F/518R	414
	V3V4	CCTACGGGNGGCWGCAG	GACTACHVGGGTATCTAATCC	17/21	71-76/43-52	4/4	341F/805R	464
	V4V5	GTGYCAGCMGCCGCGGTAA	CCGYCAATTYMTTTRAGTT	19/19	63-74/26-47	2/4	515F/926R	411
	V5V7	GGATTAGATACCCBRGTAGTC	ACGTCRTCCCCDCCTTCCTC	21/20	43-52/60-70	3/3	785F/1175R	390
ĺ	V7V9	YAACGAGCGMRACCC	TACGGYTACCTTGTTAYGACTT	15/22	53-73/36-45	3/2	1115F/1492R	377

**Supplementary Table 2: List of primers used in the first-round of PCR.** The GC content percentage (%GC) is shown as a range when primers contain degenerate bases. The degeneracy index (DI) of each primer is calculated as the sum of the number of alternate base-pairings for each degenerate base. F, forward primers; R, reverse primers.

Dataset	Total reads	Median length (F/R)	25th Q (F/R)	50th Q (F/R)	75th Q (F/R)	Q-filtered	Denoised	Merged	Non chimeras I	Non chimeras II	Bacterial	Non contaminants	% Total reads decrease	Median ASV length
V1V2	750,924	252/256	36/17	38/25	38/32	694,464	693,540	684,542	667,414	628,279	623,703	614,973	18,1	322
V2V3	801,072	253/255	37/17	38/25	38/32	716,385	715,424	710,670	673,719	647,648	641,088	624,939	22,0	380
V3V4	668,509	259/254	34/19	38/27	38/33	575,366	574,457	569,210	552,435	552,012	496,112	488,560	26,9	409
V4V5	1,674,525	253/249	35/15	38/23	38/30	1,491,565	1,490,588	616,615	614,176	613,575	484,693	477,043	71,5	373
V5V7	881,612	250/251	38/16	38/24	38/30	796,138	794,606	787,603	775,057	768,817	768,676	766,525	13,1	369
V7V9	749,534	255/249	37/17	38/25	38/32	673,733	672,883	668,883	663,163	660,085	655,224	634,974	15,3	377
Total	5,526,176					4,947,651	4,941,498	4,037,523	3,945,964	3,870,416	3,669,496	3,607,014		

**Supplementary Table 3: Reads generated per amplicon-specific dataset.** Metrics on the raw read data and the number of reads retained after each pipeline step are indicated. Only urine sample libraries are considered. Q-score (Q) percentiles are based on the position defined by the last base of the median read. Non-chimeras I and II refers, respectively, to the *de novo* chimera-filtering step within DADA2 and to the *reference-based* chimera-filtering step with VSEARCH. F, forward reads; R, reverse reads; Q-filtered, reads retained after quality-filtering.

Taxonomic rank	<b>Spearman</b> ρ	P-value
Phylum	0,65	0,16
Class	0,65	0,16
Order	-0,41	0,42
Family	-0,26	0,62
Genus	-0,26	0,66
Species	-0,58	0,23

Supplementary Table 4: Spearman correlation between taxonomic richness and the median ASV length per 16S rRNA amplicon-specific dataset.

Genus	Average RA (%)	Presence in urine	Presence in humans	
Comamonas	2,86	Liu et al., 2020	-	
Herbaspirillum	0,50	Wu et al., 2018	-	
Chryseobacterium	0,27	Zhang et al., 2021	-	
Ezakiella	0,22	Qin et al., 2021	-	
Facklamia	0,08	Mostafa et al., 2019	-	
Mycoplasma	0,04	Smolec et al., 2021	-	
Oribacterium	0,01	No	Sizova et al., 2014	
Salipaludibacillus	<0,01	No	No	
Chromohalobacter	<0,01	No	No	
Tepidimonas	<0,01	Richter et al., 2022	-	
Clostridium_sensu_stricto_1	<0,01	Mansour et al., 2020	-	
Arcanobacterium <0,01		Ben Khedher et al., 2021	-	
Lactococcus	<0,01	Newby and Ramesh, 2014	-	
Jeotgalibaca	<0,001	No	Ni et al., 2020	
Alkalibacterium	<0,001	No	No	
Sum	3,99	-	-	

**Supplementary Table 5: List of genera detected exclusively in the V1V2 dataset.** The average relative abundance (RA) over all samples is shown for each genus. References on the presence of these genera in urine samples or humans are provided.

## 2. Supplementary References

Ben Khedher, M., Lo, C. I., Diop, K., Morand, A., Armstrong, N., Raoult, D., et al. (2021). Taxonogenomics description of Arcanobacterium urinimassiliense sp. nov., a new bacterial species isolated from urine sample. *New Microbes New Infect.* 41, 100854. doi:10.1016/j.nmni.2021.100854.

Liu, F., Ling, Z., Tang, C., Yi, F., and Chen, Y. Q. (2020). Moderation effects of food intake on the relationship between urinary microbiota and urinary interleukin-8 in female type 2 diabetic patients. *PeerJ* 8, e8481. doi:10.7717/peerj.8481.

Mansour, B., Monyók, Á., Makra, N., Gajdács, M., Vadnay, I., Ligeti, B., et al. (2020). Bladder cancer-related microbiota: examining differences in urine and tissue samples. *Sci. Rep.* 10, 11042. doi:10.1038/s41598-020-67443-2.

Mostafa, H. H., Taffner, S. M., Wang, J., Malek, A., Hardy, D. J., and Pecora, N. D. (2019). Genome Sequence of a Facklamia hominis Isolate from a Patient with Urosepsis. *Microbiol. Resour. Announc.* 8, e00100-19. doi:10.1128/MRA.00100-19.

Newby, B., and Ramesh, K. K. (2014). Urinary Tract Infection in a Preterm Neonate Caused by Lactococcus lactis. *Can. J. Hosp. Pharm.* 67, 453–454. doi:10.4212/cjhp.v67i6.1409.

Ni, Q., Ye, Z., Wang, Y., Chen, J., Zhang, W., Ma, C., et al. (2020). Gut Microbial Dysbiosis and Plasma Metabolic Profile in Individuals With Vitiligo. *Front. Microbiol.* 11, 592248. doi:10.3389/fmicb.2020.592248.

Qin, J., Shi, X., Xu, J., Yuan, S., Zheng, B., Zhang, E., et al. (2021). Characterization of the Genitourinary Microbiome of 1,165 Middle-Aged and Elderly Healthy Individuals. *Front. Microbiol.* 12, 673969. doi:10.3389/fmicb.2021.673969.

Richter, H. E., Carnes, M. U., Komesu, Y. M., Lukacz, E. S., Arya, L., Bradley, M., et al. (2022). Association between the urogenital microbiome and surgical treatment response in women undergoing midurethral sling operation for mixed urinary incontinence. *Am. J. Obstet. Gynecol.* 226, 93.e1-93.e15. doi:10.1016/j.ajog.2021.07.008.

Sizova, M. V., Muller, P. A., Stancyk, D., Panikov, N. S., Mandalakis, M., Hazen, A., et al. (2014). Oribacterium parvum sp. nov. and Oribacterium asaccharolyticum sp. nov., obligately anaerobic bacteria from the human oral cavity, and emended description of the genus Oribacterium. *Int. J. Syst. Evol. Microbiol.* 64, 2642–2649. doi:10.1099/ijs.0.060988-0.

Smolec, D., Ekiel, A., Kłuciński, P., and Kawecki, J. (2021). Occurrence of urogenital mycoplasmas in men with the common genitourinary diseases. *Braz. J. Microbiol. Publ. Braz. Soc. Microbiol.* 52, 2013–2019. doi:10.1007/s42770-021-00620-1.

Wu, P., Zhang, G., Zhao, J., Chen, J., Chen, Y., Huang, W., et al. (2018). Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. *Front. Cell. Infect. Microbiol.* 8, 167. doi:10.3389/fcimb.2018.00167.

Zhang, Y., Li, D., Yang, Y., Su, J., Xu, X., Wang, M., et al. (2021). Clinical and molecular characteristics of Chryseobacterium indologenes isolates at a teaching hospital in Shanghai, China. *Ann. Transl. Med.* 9, 668. doi:10.21037/atm-21-933.